Recombinant IL-1Ra Stimulation of Native NP Cells Inhibits a Multitude of Pathological Features (original) (raw)

Interleukin-1 receptor antagonist (IL-1Ra) demonstrates potential as a therapeutic agent in mitigating pathological features associated with intervertebral disc degeneration. This study investigates the effects of IL-1Ra on human nucleus pulposus cells, revealing a decrease in catabolic factors such as matrix metalloproteases, cytokines, and growth factors. Patient variability in response to IL-1Ra suggests the necessity for tailored therapeutic approaches. Inhibition of IL-1 can lead to improved tissue microenvironments desirable for regeneration, but careful consideration of dosing based on individual patient responses is crucial for effective application.